Heron Therapeutics (HRTX) Non Operating Income (2010 - 2020)
Heron Therapeutics' (HRTX) quarterly Non Operating Income came in at -$985000.0 in Q4 2020, down 168.31% YoY from $1.4 million in Q1 2020, and down 731.41% on a QoQ basis from $156000.0 in Q3 2020.
Heron Therapeutics (HRTX) Non Operating Income (2010 - 2020) Analysis & Trends
Heron Therapeutics (HRTX) has 11 years of Non Operating Income data on file, last reported at -$985000.0 in Q4 2020.
- Quarterly Non Operating Income fell 168.31% year-over-year to -$985000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $885000.0 (down 85.11% YoY) and the FY2025 annual result came in at -$17.7 million, down 760.48% from the prior year.
- Non Operating Income declined to -$985000.0 in Q4 2020, from $156000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $3.4 million in Q3 2018 to a low of -$1.2 million in Q4 2016.
- A 5-year average of $363473.7 and a median of $156000.0 in 2020 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2017 — Non Operating Income tumbled 365.0% — and 2019, when it soared 750.82%.
- Tracing HRTX's Non Operating Income over 5 years: stood at -$1.2 million in 2016, then jumped by 48.28% to -$600000.0 in 2017, then soared by 392.5% to $1.8 million in 2018, then dropped by 17.83% to $1.4 million in 2019, then plunged by 168.31% to -$985000.0 in 2020.
- The last three Non Operating Income figures came in at -$985000.0 (Q4 2020), $156000.0 (Q3 2020), and $559000.0 (Q2 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Heron Therapeutics | 59.96 Mn | 17.29 Mn | 26.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -985,000.00 |
| Sep 30, 2020 | 156,000.00 |
| Jun 30, 2020 | 559,000.00 |
| Mar 31, 2020 | 1.16 Mn |
| Dec 31, 2019 | 1.44 Mn |
| Sep 30, 2019 | 1.26 Mn |
| Jun 30, 2019 | 1.56 Mn |
| Mar 31, 2019 | 1.69 Mn |
| Dec 31, 2018 | 1.76 Mn |
| Sep 30, 2018 | 3.43 Mn |
| Jun 30, 2018 | 183,000.00 |
| Mar 31, 2018 | -275,000.00 |
| Dec 31, 2017 | -600,000.00 |
| Sep 30, 2017 | -552,000.00 |
| Jun 30, 2017 | -744,000.00 |
| Mar 31, 2017 | -1.03 Mn |
| Dec 31, 2016 | -1.16 Mn |
| Sep 30, 2016 | -775,000.00 |
| Jun 30, 2016 | -160,000.00 |
| Mar 31, 2015 | -210,000.00 |